Gokyer, AliKucukarda, AhmetCicin, Irfan2024-06-122024-06-122020978-625-401-191-7https://hdl.handle.net/20.500.14551/21763Two-thirds of all new cancer diagnoses are made in persons over the age of 65 years. It is unclear if age affects patient respons to immunotherapy, which is increasingly becoming first-line therapy in advanced stages of different tumor types. As a result of data obtained from different immunotherapy studies, it was seen that advanced age did not change safety and response. In these studies, it was found that drugs were generally in low toxicity profile and well tolerated in elderly and young patient subgroups. However, there are drug-specific differences for immune check-point inhibition in comparison of young patients and overall survival and progression-free survival rates in elderly individuals. Further studies should be conducted on patients who respond to and do not give medication to optimize the use of immunotherapy in elderly patients.trinfo:eu-repo/semantics/closedAccessImmunotherapyCancer SurvivorsDrug-Related Side Effects And Adverse ReactionsSquamous-Cell CarcinomaDouble-BlindIpilimumabPembrolizumabMulticenterMelanomaNivolumabRecurrentEfficacyPlaceboBook Chapter106109N/AWOS:000773800000018